Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) and Evogene (NASDAQ:EVGN – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk.
Insider and Institutional Ownership
86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 9.4% of Bolt Biotherapeutics shares are held by company insiders. Comparatively, 7.4% of Evogene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Bolt Biotherapeutics and Evogene”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bolt Biotherapeutics | $7.70 million | 0.90 | -$33.38 million | ($16.44) | -0.22 |
| Evogene | $3.85 million | 1.12 | -$8.48 million | ($0.91) | -0.54 |
Evogene has lower revenue, but higher earnings than Bolt Biotherapeutics. Evogene is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Bolt Biotherapeutics has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Evogene has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for Bolt Biotherapeutics and Evogene, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bolt Biotherapeutics | 1 | 1 | 2 | 0 | 2.25 |
| Evogene | 1 | 0 | 0 | 0 | 1.00 |
Bolt Biotherapeutics presently has a consensus price target of $14.50, indicating a potential upside of 302.11%. Given Bolt Biotherapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Bolt Biotherapeutics is more favorable than Evogene.
Profitability
This table compares Bolt Biotherapeutics and Evogene’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bolt Biotherapeutics | -611.47% | -126.23% | -54.70% |
| Evogene | -694.18% | -156.53% | -86.80% |
Summary
Bolt Biotherapeutics beats Evogene on 10 of the 14 factors compared between the two stocks.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
